Bicycle Therapeutics Ltd (BCYC)

NASDAQ
42.35
+0.33(+0.79%)
After Hours
42.00
+0.15(+0.36%)
- Real-time Data
  • Volume:
    145,851
  • Bid/Ask:
    15.50/71.36
  • Day's Range:
    40.00 - 43.83

BCYC Overview

Prev. Close
42.02
Day's Range
40-43.83
Revenue
11.28M
Open
42.32
52 wk Range
17.68-45.21
EPS
-2.83
Volume
145,851
Market Cap
1.07B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
171,063
P/E Ratio
-
Beta
-
1-Year Change
103.61%
Shares Outstanding
25,509,312
Next Earnings Date
Nov 11, 2021
What is your sentiment on Bicycle Therapeutics Ltd?
or
Market is currently closed. Voting is open during market hours.

Bicycle Therapeutics Ltd News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellNeutralBuyStrong Buy
Technical IndicatorsStrong SellStrong SellBuyStrong BuyStrong Buy
SummaryStrong SellStrong SellNeutralStrong BuyStrong Buy

Bicycle Therapeutics Ltd Company Profile

Bicycle Therapeutics Ltd Company Profile

Employees
87

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company’s oncology product candidates also comprise BT5528, a BTC that is in a Phase I/IIa clinical trial targeting EphA2; BT8009, which is in preclinical studies targeting Nectin-4; and CD137, an immune cell co-stimulatory molecule that is in preclinical stage. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase I clinical trials for the treatment of diabetic macular edema. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and CRUK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.